Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunoMRI for Macrophage Assessment in DLBCL
NCT07066436Phase 1Not yet recruiting
- Sponsor
- Medical University of Vienna
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ferumoxytol in diffuse large B-cell lymphoma (DLBCL), sponsored by Medical University of Vienna. Primary endpoints: Correlation between immunoMRI and M1 and M2 TAM-directed IHC at 3 years, Prediction of complete remission (CR) at 3 years and 3 more. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
ferumoxytol
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07066436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07066436.